"Designing Growth Strategies is in our DNA"
The global anti-inflammatory drugs market size was USD 93.88 billion in 2019 and is projected to reach USD 191.42 billion by 2027, exhibiting a CAGR of 9.3% during the forecast period.
Non-steroidal Anti-inflammatory Drugs (NSAIDs) are used as a primary treatment option for pain and inflammation. Many government associations such as the Centers for Disease Control and Prevention advises the use of NSAIDs over opioids. According to a press release of Endo International plc, about 84 million NSAIDs prescriptions are written annually in the U.S. Apart from this, anti-inflammatory biologics is emerging as a shining star in the market. Research on anti-tumor necrosis factor (TNF), interleukins, janus kinase inhibitors, and new product launches are expected to fuel the market. Also, the rising prevalence of autoimmune inflammatory diseases and growing preference for biosimilars are anticipated to augment the market.
Request a sample to learn more about this report.
Focus on Developing Biosimilars by Key Pharmaceutical Companies to Augment the Market
Patent expiration of top anti-inflammatory biologics paved its way for the entry of biosimilars in the market. Many manufactures have shifted their focus to the development of biosimilars owing to the increasing demand and easy approval process when compared to a new drug. This has become an important market trend. Biosimilars of adalimumab, infliximab, and etanercept are aiming at attracting high revenue in the market with their reference biologics namely Humira, Ramicade, and Enbrel. A total of 5 biosimilar of AbbVie’s blockbuster drug Humira are approved by the FDA which are likely to belaunched in 2023 in the U.S. While in other regions such as Europe, the adalimumab biosimilar is now commercially available. Moreover, clinical research for developing biosimilars of reference biologics that are about to lose exclusivity in coming years have already been initiated. This is likely to propel the demand for anti-inflammatory therapeutics in the coming years.
Potential Pipeline Candidates to Boost Market
Increasing research investments for the development of biologics for the treatment of autoimmune inflammatory diseases has resulted in potential pipeline drugs. The benefits of anti-inflammatory properties of monoclonal antibodies have shifted the focus of pharmaceutical giants towards this area. The companies are focusing on targeting broad inflammatory diseases with anti-tumor necrosis factor (TNF) inhibitors, interleukins, and others. For example, in December 2019, UCB S.A. announced positive results from the phase 3 clinical study of Bimekizumab for the treatment of psoriasis. Apart from this, research and development of NSAIDs and corticosteroids for treating atopic dermatitis, plaque psoriasis, acute pain, and others are projected to drive the anti-inflammatory drugs market in the forecast period.
Rising Prevalence of Inflammatory Diseases to Aid in Favor of Market
Rising prevalence of inflammatory diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ulcerative colitis, and others is one of the leading factors driving the anti-inflammatory therapeutics market growth. According to the Centers for Disease Control and Prevention, 78 million adults in the U.S. are estimated to have doctor-diagnosed arthritis by 2040. This is expected to fuel the market during the forecast period. Furthermore, the rising uptake of corticosteroids for the treatment of asthma and chronic obstructive pulmonary disease (COPD) and the rising prevalence of atopic dermatitis are expected to add impetus to market.
Side Effects of NSAIDs are Likely to Hinder Market Growth
Side effects from the Non-Steroids Anti-inflammatory drugs (NSAIDs) such as stomach ulcers, allergic reactions, dizziness, stomach pain, and others are expected to restrict market growth. NSAIDs are among the most commonly prescribed medications as they are effective anti-inflammatory agents. However, NSAIDs-related gastrointestinal complications possess a potential burden on the healthcare system. GI bleeding is the most common reason for a majority of hospital admissions. In the U.S., NSAIDs-related GI complications have become the most common side effect. This is expected to negatively impact the market revenue in the coming years.
To know how our report can help streamline your business, Speak to Analyst
Anti-inflammatory Biologics Segment to Dominate Market Due to High Drug Sales
On the basis of drug class, the market is segmented into anti-inflammatory biologics, Non-steroidal Anti-inflammatory Drugs (NDAIDs), and corticosteroids. The anti-inflammatory biologics segment accounted for the maximum share in 2019. New product launches, rapid adoption of monoclonal antibodies, and entry of biosimilars are the primary reasons for the growth of this segment. In August 2019, AbbVie announced the launch of RINVOQ, a janus kinase inhibitor for the treatment of rheumatoid arthritis. The NSAIDs segment is anticipated to expand owing to the rising prevalence of inflammatory diseases, expanding applications of NSAIDs, and increasing demand for over-the-counter (OTC) anti-inflammatory therapeutics. Moreover, government recommendations for the use of NSAIDs as the first line of treatment for pain and inflammation are also boosting the demand for NSAIDs. The corticosteroid segment is likely to grow owing to the rising prevalence of COPD, increased research, and potential pipeline candidates.
Rising Prevalence of Arthritis to Drive the Autoimmune Inflammatory Diseases Segment
Based on application, the market is segmented into autoimmune inflammatory diseases, respiratory diseases, and others. The autoimmune inflammatory diseases segment can be further bifurcated into rheumatoid arthritis, psoriasis, and others. The autoimmune inflammatory disease segment is estimated to generate maximum revenue in 2019. Primary reasons for the growth of the segment are rising prevalence of rheumatoid arthritis, inflammatory bowel diseases, and psoriasis. The respiratory diseases segment is projected to expand during the forecast period owing to a significant increase in the number of COPD cases and rising uptake of inhaled corticosteroids. The others segment comprises of diseases such as atopic dermatitis, eye diseases, migraine, and others. The rising application of anti-inflammatory drugs in the treatment of various diseases, potential pipeline candidates, and favorable health reimbursement is expected to augment the others segment.
Rising Adoption of Anti-inflammatory biologics to Render Leading Position to the Injection Segment
On the basis of route of administration, the market is segmented into oral, injection, inhalation, and topical. The injection segment is estimated to emerge dominant during the forecast period as almost all the anti-inflammatory biologics are administrated through injections. Focus to launch of oral anti-inflammatory therapeutics, higher sales of Advil, and the increasing availability of generic products are factors contributing to the expansion of the oral segment. Furthermore, the rapid adoption of topical drugs and increasing demand for inhaled corticosteroids are expected to augment the inhalation and topical segmentsbetween2020-2027.
Hospital Pharmacy to Account for Major Portion of Market
In terms of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2018 owing to the increasing number of prescriptions for anti-inflammatory drugs, favorable health reimbursement, and the rising prevalence of inflammatory diseases. Increased availability of over-the-counter (OTC) drugs, and growing demand for diclofenac, and ibuprofen are likely to foster the retail pharmacy segment. In April 2018, Strides Pharma Inc. received US FDA approval for Ibuprofen OTC capsules which is expected to augment the retail pharmacy segment. The online segment is poised to grow owing to the rising adoption of e-commerce, improving patient convenience, and attractive discounts and coupons on online sales.
North America Anti-Inflammatory Drugs Market Size, 2016-2027 (USD Billion)
To get more information on the regional analysis of this market, Request a sample
The anti-inflammatory drugs market in North America stood at USD 41.39 billion in 2019. Increasing demand for anti-inflammatory biologics, government-support for the launch of biosimilars, and significant research investments are the major factors attributable to the expansion of the market in North America. Furthermore, increased sales of Humira, Ramicade, and Enbrel and recommendation from the Centers for Disease Control and Prevention on the use of non-opioid drugs will further help the market to flourish. The demand for anti-inflammatory therapeutics is poised to surge in Europe owing to the active government support for the launch of biosimilars and favorable health reimbursement policies. In October 2018, Amgen announced the launch of Amgevita, a biosimilar of adalimumab in Europe. This is anticipated to foster the market in Europe. Increasing uptake of OTC anti-inflammatory drugs, rising geriatric population, and more preference for generic NSAIDs and corticosteroids are projected to expand the market in Asia Pacific. Factors attributed to the expansion of the markets in Latin America and the Middle East & Africa are rising incidence of rheumatoid arthritis, improving the health infrastructure, and shift of manufacturers focus towards these regions.
AbbVie and Johnson & Johnson to Account for Leading Position
In terms of revenue, AbbVie accounted for the maximum portion of the market. This can be attributed to the higher sales of Humira, a multiple indication monoclonal antibody for multiple indications such as rheumatoid arthritis, psoriasis arthritis, ulcerative colitis, and others. In 2019, the company generated US$ 19.2 billion solely from the sale of Humira. Similarly, the high sales of Remicade, Stelara, and Simponi rendered the second position to Johnson and Johnson. However, the introduction of biosimilars for adalimumab and infliximab especially in major markets such as the U.S. and Europe is expected to negatively impact the revenues of the companies.
The anti-inflammatory drugs market report offers a detailed analysis of numerous factors aiding the market both positively and negatively. These include opportunities, growth drivers, threats, key developments, and restraints. In addition to this, the report further helps in analyzing, segmenting, and defining the market based on different segments such as drug class, application, route of administration, and distribution channel. It also provides various key insights such as prevalence of major diseases for key countries, patent snapshot, pipeline analysis, new product launches, key mergers& acquisition, joint ventures, and others.
To gain extensive insights into the market, Request for Customization
Value (USD billion)
By Drug Class
By Route of Administration
By Distribution Channel
The value of the global market was USD 93.88 billion in 2019.
Fortune Business Insights says that the market is projected to reach USD 191.42 billion by 2027.
The value of the market in North America was USD 41.39 billion in 2019.
The market is projected to rise at a CAGR of 9.3% during the forecast period (2020-2027).
Anti-inflammatory biologics is the leading segment in this market during the forecast period.
Rising prevalence of inflammatory diseases and potential pipeline products are the key factors driving the market.
AbbVie Inc. and Johnson & Johnson Services, Inc. are the top players in the market.
North America is expected to hold the highest market share.
Focus on developing biosimilars and novel therapeutics is the key trend of the market.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry